Sulfad is a phytopharmaceutical bioactive compound including CAF-6 & CAF-8 (main active ingredient 1,5 dicaffeoylquinic acid, also known as cynarine), Mariana90 (main active ingredient > 70% silibinin or (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl]chroman-4-one), Glyc-6 (main active ingredient glycyrrhizinic acid or (3β,18α)-30-hydroxy-11,30-dioxoolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-β-D-glucopyranosiduronic acid), turmeric (main active ingredient C.I. 75300 or (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione).[clarification needed]
Sulfad is used in the management of different liver diseases including steatosis, steatohepatitis and viral hepatitis. It acts as potent antioxidant and hepatoprotective agent. Also it reduces triglycerides and LDL by different mechanisms.
Oxidative stress is defined as structural and/or functional injury produced in tissues by the uncontrolled formation of pro-oxidant free radicals. Sulfad preserves the functional and structural integrity of hepatocyte membranes by preventing alterations of their phospholipid structure and by restoring alkaline phosphatase and gamma-glutamyl transpeptidase activities. Cynarine in Sulfad plays a major role in the prevention of oxidative damage to hepatocyte membranes.
Anti-inflammatory and anti-carcinogenic effects
Studies have shown that one of Sulfad's active constituents has a number of effects including inhibition of neutrophil migration, marked inhibition of leukotriene synthesis and formation of prostaglandins.
Sulfad produced a significant increase in the formation of ribosomes and in DNA synthesis, as well as an increase in protein synthesis. Interestingly, the increase in protein synthesis was induced by Sulfad only in injured livers, not in healthy controls.
As could be shown with isolated hepatocytes, Sulfad acts directly on the metabolism of the cell nucleus. Sulfad lead a normalization of the pathologically altered protein synthesis by increasing RNA synthesis. This improvement or normalization of the plasma protein picture, having been proven in several clinical studies.
||This article has an unclear citation style. (June 2010)|
- P. Rohdewald , Adolf Nahrstedt (2010). "Efficacy and safety of Sulfad tablets in viral hepatitis: A prospective,double-blind, randomized, placebo-controlled, phase III clinical trial". Phytopharmacy.
- Saller R, Meier R, Brignoli R (2001). "The use of silymarin in the treatment of liver diseases". Drugs 61 (14): 2035–63. doi:10.2165/00003495-200161140-00003. PMID 11735632.
- Kim, Hye Jin; Yoo, Hwa Seung; Kim, Jin Chul; Park, Chan Su; Choi, Mi Sun; Kim, Mijee; Choi, Hyangsoon; Min, Jung Sun et al. (2009). "Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication". Journal of Ethnopharmacology 124 (2): 189–96. doi:10.1016/j.jep.2009.04.046. PMID 19409970.
- Ali-Akbar Hajaghamohammadi, Amir Ziaee*, Ramin Rafiei (2008). "The Efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial". Hepatitis Monthly 8 (3): 191–195.
- Jayaraj, R.; Deb, Utsab; Bhaskar, A. S. B.; Prasad, G. B. K. S.; Rao, P. V. Lakshmana (2007). "Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice". Environmental Toxicology 22 (5): 472–9. doi:10.1002/tox.20283. PMID 17696131.